PMA device
Optimum Infinite (tisilfocon A) Orthokeratology Lenses II
Contamac, Ltd. · Lens, Contact, Orthokeratology, Overnight (NUU, Class III) · First FDA decision Feb 10, 2026, newest Feb 10, 2026Nearsightedness and refractive error
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Optimum Infinite"
MAUDE reports
0
Brand "Optimum Infinite", since 2015
PubMed studies
0
Mentioning "Optimum Infinite"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Optimum Infinite (tisilfocon A) Orthokeratology Lenses II
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P240045 · Decided Feb 10, 2026 · 420 days after receipt
Device type: Lens, contact, orthokeratology, overnight (NUU) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Optimum Infinite", any status and sponsor, newest update first.
Erica TeixeiraAcademic, hospital or other
NCT03716349 · 36 participants · Start Jan 1, 2019 · Primary completion Nov 20, 2025
Device: rubber dam; Tokuyama Universal Bond and 1 more · For: Cavities of Teeth
Sites: Iowa City, Iowa
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Optimum Infinite", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NUU
40 reports: 3 malfunction, 37 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Optimum Infinite"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NUU.
- Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) ContactEuclid Vision Corporation · PMA 2026
- Boston Orthokeratology (oprifocon A) Shaping lens for Overnight Wear for Bausch + Lomb Vision Shaping TreatmentBausch & Lomb · PMA 2025
- Menicon Z Night (tisilfocon A) Contact Lenses for Overnight WearMenicon Co, Ltd. · PMA 2022
- Paragon Z CRT (tisilfocon A) and Paragon Z CRT Dual Axis (tisilfocon A) Rigid Gas Permeable Contact lenses in blue tintCooperVision, Inc. · PMA 2019
- Jsz Orthokeratology (Oprifocon A) Contact Lenses for Overnight WearEuclid Vision Corporation · PMA 2016
- DilightTM (roflufocon E) Overnight Orthokeratology Contact LensTianjin MasterVision Technology Co., Ltd. · PMA 2026
- ACUVUE® Abiliti Overnight and ACUVUE® Abiliti Overnight Therapeutic Lenses for Myopia ManagementMenicon Co, Ltd. · PMA 2021
- Orthokeratology (tisilfocon A) Contact Lenses for Overnight WearEuclid Vision Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.